Teladoc Health Inc. [TDOC] shares are up more than 146.53% this year and recently decreased -0.03% or -$6.36 to settle at $197.30. Analysts expect TDOC to shrink earnings at a -0.92% annual rate over the next 5 years. TDOC has a short ratio of 4.79. This implies that the market is currently less bearish on the outlook for TDOC.
On 3, December 2020, Leading the $2.8 Trillion US Healthcare Market: CEO’s of Oak Street Health, Skylight Health, 1life Healthcare and Teladoc – Driving Explosive Revenue Growth with Innovation and New Market Expansions. According to news published on Yahoo Finance, Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: 1life Healthcare (NASDAQ: ONEM), Skylight Health Group (CSE: SHG) (OTC: CBIIF), Teladoc Health (NYSE: TDOC), and Oak Street Health (NYSE: OSH).
Analyst Birdseye View:
The most recent analyst activity for Teladoc Health Inc. [NYSE:TDOC] stock was on December 04, 2020, when it was Initiated with a Neutral rating from Goldman, which also raised its 12-month price target on the stock to $206. Before that, on December 07, 2020, Stephens Recapitulated an Equal-weight rating and elevated its amount target to $210. On November 13, 2020, Robert W. Baird Upgrade an Outperform rating and boosted its price target on this stock to $220. On September 22, 2020, DA Davidson Initiated a Buy rating and increased its price target to $250. On September 02, 2020, Berenberg Upgrade a Buy rating and increased its price target to $252. On August 17, 2020, Credit Suisse Upgrade an Outperform rating and boosted its amount target on this stock to $249. On July 14, 2020, Citigroup Initiated a Buy rating and boosted its target amount on this stock to $275. On July 13, 2020 Argus Initiated a Buy rating and elevated its amount target to $280.
In the past 52 weeks of trading, this stock has oscillated between a low of $75.20 and a peak of $253.00. Right now, the middling Wall Street analyst 12-month amount mark is $247.50. At the most recent market close, shares of Teladoc Health Inc. [NYSE:TDOC] were valued at $197.30. According to the average price forecast, investors can expect a potential return of 0.12%.
Teladoc Health Inc. [NYSE:TDOC] most recently reported quarterly sales of 288.81 billion, which represented growth of 109.30%. This publicly-traded organization’s revenue is $230,545 per employee, while its income is -$41,193 per employee. This company’s Gross Margin is currently 62.70%, its Operating Margin is -8.40%, its Pretax Margin is -19.78, and its Net Margin is -17.87. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -6.36, -9.75, -4.61 and -6.80 respectively.
If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 31.69 and the whole liability to whole assets at 28.13. It shows enduring liability to the whole principal at 31.35 and enduring liability to assets at 0.28 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 194.63 points at 1st support level, the second support level is making up to 191.97. But as of 1st resistance point, this stock is sitting at 201.39 and at 205.49 for 2nd resistance point.
Teladoc Health Inc. [TDOC] reported its earnings at -$0.43 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.32/share signifying the difference of -0.11 and -34.40% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.34 calling estimates for -$0.23/share with the difference of -0.11 depicting the surprise of -47.80%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for Teladoc Health Inc. [NYSE:TDOC] is 6.50. Likewise, the Quick ratio is also the same, showing Cash ratio at 5.73. Now if looking for a valuation of this stock’s amount to sales ratio it’s 10.87 and it’s amount to book ratio is 6.01.
The most recent insider trade was by WANG YULUN, Head of Research & Development, and it was the sale of 6069.0 shares on Dec 04. Verstraete Stephany, the Chief Marketing Officer, completed a sale of 2000.0 shares on Dec 04. On Dec 03, Vandervoort Adam C, Chief Legal Officer, Secretary, completed a sale of 2611.0 shares.